Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Inclusion Criteria: * Undergoing autologous stem cell transplant for one of the following diagnoses: * Multiple myeloma * Non-Hodgkin lymphoma * Karnofsky performance status of \>= 70% * Patients must meet the Thomas Jefferson University Hospital (TJUH) bone marrow transplant (BMT) standard of procedure (SOP) guidelines for "Patient Criteria for Autologous HSCT" * Left ventricular ejection fraction (LVEF) of ≥ 40% * Adjusted Carbon monoxide diffusing capability (DLCO) \> 45% of predicted corrected for hemoglobin * Serum bilirubin \< 1.8 * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5 X upper limit of normal * Serum creatinine =\< 2.0 mg/dl and/or creatinine clearance of \> 40 ml/min (excludes multiple myeloma patients receiving high dose melphalan conditioning) * Willingness to use contraception if childbearing potential * Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process * Life expectancy of \> 12 months (exclusive of the disease for which the auto HSCT is being performed) * Patients must have undergone stem cell mobilization with the combination of G-CSF and plerixafor as per TJUH BMT SOP guidelines * Collection of an adequate number of CD34+ stem cells, i.e. \>= 4-6 x 10\^6/kg from apheresis Exclusion Criteria: * Uncontrolled human immunodeficiency virus (HIV) * Uncontr…